Follow the 리가켐바이오 stock price and the full directors' dealings record of the company, a listed issuer based in South Korea. Shares trade on the KR market, under the authority of DART (FSS). Operating in the Health Care sector, 리가켐바이오 has logged 25 public disclosures. The latest transaction was reported on 1 October 2025 (Purchase). Among the most active insiders: 김용주. Every trade is accessible without an account.
25
Insider Decl.
n/a
Thresholds
n/a
19 ops.
Buy Volume
n/a
2 ops.
Sell Volume
7Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.